Dr. David N. Barrera, DO
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 500
Licensed in Texas since 1994, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license J6320 (first issued 1994; active) -
Hematology & Oncology Physician
TX license J6320 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Texas Health Harris Methodist Fort Worth Fort Worth, TX
- Baylor Scott and White All Saints Medical Center Fort Worth, TX
- Texas Health Harris Methodist Hospital Southwest F Fort Worth, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 500
- Services billed
- 81,342
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, iron sucrose, 1 mg | 14,300 | 23 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6,010 | 64 |
| Injection, pembrolizumab, 1 mg | 5,400 | 11 |
| Injection, denosumab, 1 mg | 960 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 940 | 39 |
| Insertion of needle into vein for collection of blood sample | 840 | 345 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 806 | 335 |
| Blood test, comprehensive group of blood chemicals | 720 | 319 |
| Established patient office or other outpatient visit, 30-39 minutes | 611 | 266 |
| Injection, granisetron hydrochloride, 100 mcg | 360 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Fort Worth, TX | 210 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Fort Worth, TX | 106 |
| Eliquis (apixaban) Other prescribers in Fort Worth, TX | 102 |
| Hydroxyurea Other prescribers in Fort Worth, TX | 64 |
| Warfarin Sodium Other prescribers in Fort Worth, TX | 62 |
| Folic Acid Other prescribers in Fort Worth, TX | 59 |
| Xarelto (rivaroxaban) Other prescribers in Fort Worth, TX | 46 |
| Anastrozole Other prescribers in Fort Worth, TX | 41 |
| Lenalidomide | 38 |
| Prednisone Other prescribers in Fort Worth, TX | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 80 payments worth $2,556 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,014 |
|---|---|
| Pfizer Inc. | $141 |
| Incyte Corporation | $130 |
| Janssen Biotech, Inc. | $114 |
| AstraZeneca Pharmaceuticals LP | $111 |
| Sobi, Inc | $108 |
| E.r. Squibb & Sons, L.l.c. | $97.73 |
| Merck Sharp & Dohme LLC | $81.12 |
| Food and Beverage | $1,556 |
|---|---|
| Long term medical supply or device loan | $1,000 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.